XImmune Overview

  • Founded
  • 2009
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

XImmune General Information


Developer of a drug research center designed to turn natural immunity into drugs. The company's drug research center utilize endogenous peptides as novel modulators to develop a peptide-based anti-inflammatory treatment for sepsis, enabling patients to consume necessary drugs without any side effects.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • LU Innovation System
  • Box 117
  • 221 00 Lund
  • Sweden
+46 076-828 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

XImmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Oct-2015 Completed Out of Business
3. Buyout/LBO (Secondary) 00.000 Completed Startup
2. Secondary Transaction - Private 01-Jan-2009 $1.36M Completed Startup
1. Early Stage VC $1.36M $1.36M Completed Startup
To view XImmune’s complete valuation and funding history, request access »

XImmune Board Members (7)

Name Representing Role Since
Artur Schmidtchen Self Board Member & Co-Founder 000 0000
IngaLill Larsson Self Chairman 000 0000
Martin Malmsten Self Board Member & Co-Founder 000 0000
Olof Tydén Ph.D Self Board Member 000 0000
Sven Andreasson Self Chairman of the Board 000 0000
You’re viewing 5 of 7 board members. Get the full list »